Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
MPH Medicure	C$1.05 -8.7%	C$1.17	C$0.63 ▼ C$1.27	C$10.96M	0.9	4,260 shs	4,200 shs
VIR Vir Biotechnology	$4.58 +4.6%	$5.13	$4.16 ▼ $14.45	$636.24M	1.18	1.04 million shs	1.19 million shs
ZOM Zomedica		$0.12	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
MPH Medicure	0.00%	-8.70%	-16.00%	+11.70%	+3.96%
VIR Vir Biotechnology	+4.57%	+1.33%	-21.71%	+1.78%	-47.17%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	-30.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MPH Medicure	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	3.4182 of 5 stars	3.4	2.0	0.0	0.0	3.2	3.3	1.3
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	0.00	N/A	N/A	N/A
MPH Medicure	0.00	N/A	N/A	N/A
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	560.48% Upside
ZOM Zomedica	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MPH, HEXO, VIR, and ZOM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
MPH Medicure	C$21.08M	0.52	C$0.42 per share	2.49	C$1.91 per share	0.55
VIR Vir Biotechnology	$74.21M	8.57	N/A	N/A	$6.82 per share	0.67
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
MPH Medicure	-C$2.03M	-C$0.19	N/A	∞	N/A	-9.65%	-10.18%	-5.63%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest MPH, HEXO, VIR, and ZOM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
MPH Medicure	N/A	2.24%	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	0.01	0.41	0.24
MPH Medicure	4.65	2.03	1.29
VIR Vir Biotechnology	N/A	7.01	7.01
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.78%
MPH Medicure	23.10%
VIR Vir Biotechnology	65.32%
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
HEXO HEXO	4.69%
MPH Medicure	26.68%
VIR Vir Biotechnology	16.00%
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
MPH Medicure	N/A	10.44 million	N/A	Not Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

MPH, HEXO, VIR, and ZOM Headlines

Recent News About These Companies

Zomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19, 2025 | finanznachrichten.de

Zomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

August 12, 2025 | finanznachrichten.de

Zomedica Achieves Record Revenue Growth in Q2 2025

August 6, 2025 | msn.com

Non-Pharmacologic Solutions for Pet Dental Health From Prevention to Recovery

July 11, 2025 | dvm360.comD

Zomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - Ocala

July 10, 2025 | finanznachrichten.de

Zomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - Morningstar

June 25, 2025 | morningstar.comM

Zomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

May 20, 2025 | finanznachrichten.de

Treat pet pain, inflammation, and anxiety with this high-tech at home therapy

April 24, 2025 | click2houston.comC

Helping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family Members

April 11, 2025 | pix11.comP

Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?

March 28, 2025 | insidermonkey.com

15 Cheapest Stocks Insiders Are Buying In March

March 27, 2025 | insidermonkey.com

Earnings call transcript: Zomedica Q4 2024 shows revenue growth

March 15, 2025 | investing.com

Q4 2024 Zomedica Corp Earnings Call

March 15, 2025 | finance.yahoo.com

Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript

March 13, 2025 | seekingalpha.com

Zomedica (ZOMDF) Gets a Buy from Noble Financial

March 11, 2025 | markets.businessinsider.com

Zomedica Corp.

March 8, 2025 | wsj.com

Zomedica Corp. Announces Transition to OTCQB Venture Market

March 4, 2025 | accessnewswire.comA

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

March 4, 2025 | businesswire.com

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

February 26, 2025 | accessnewswire.comA

Zomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MPH, HEXO, VIR, and ZOM Company Descriptions

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

Medicure CVE:MPH

C$1.05 -0.10 (-8.70%)

As of 08/22/2025 01:13 PM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Vir Biotechnology NASDAQ:VIR

$4.58 +0.20 (+4.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.61 +0.03 (+0.55%)

As of 08/22/2025 07:58 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time